S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Moldova signs new energy deal that could ease blackout risk
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Moldova signs new energy deal that could ease blackout risk
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Moldova signs new energy deal that could ease blackout risk
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
OPEC+ oil producers face uncertainty over Russian sanctions
Moldova signs new energy deal that could ease blackout risk
Negative News Sentiment  
NASDAQ:MYGN

Myriad Genetics - MYGN Stock Forecast, Price & News

$20.93
+0.59 (+2.90%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.71
▼
$21.00
50-Day Range
$15.78
▼
$20.99
52-Week Range
$15.38
▼
$28.45
Volume
464,030 shs
Average Volume
575,219 shs
Market Capitalization
$1.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.50

Myriad Genetics MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
21.8% Upside
$25.50 Price Target
Short Interest
Bearish
5.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.79) to ($0.54) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.41 out of 5 stars

Medical Sector

963rd out of 1,034 stocks

Diagnostic Substances Industry

13th out of 15 stocks

See Top Rated MarketRank™ Stocks Here
MYGN stock logo

About Myriad Genetics (NASDAQ:MYGN) Stock

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Stock News Headlines

November 29, 2022 | finance.yahoo.com
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
November 17, 2022 | finance.yahoo.com
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
December 4, 2022 | Legacy Research (Affiliate) (Ad)
The One Ticker Retirement Plan Over the Shoulder Demo Now Available
Market Wizard Larry Benedict crushed the market in 2022. But he hasn’t done it with a “traditional” method… For a limited time, he’s sharing a free over-the-shoulder “demo” of his strategy in action. It takes less than 10 seconds…
November 14, 2022 | finance.yahoo.com
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
November 10, 2022 | finance.yahoo.com
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
November 4, 2022 | finance.yahoo.com
Why Shares of Myriad Genetics Dropped 24% This Week
November 3, 2022 | forbes.com
Myriad Genetics (MYGN) To Share Guarded BRCA Variant Information In Public Database
November 3, 2022 | seekingalpha.com
Myriad Genetics: All You Need To Know About Q3 Earnings
December 4, 2022 | Legacy Research (Affiliate) (Ad)
The One Ticker Retirement Plan Over the Shoulder Demo Now Available
Market Wizard Larry Benedict crushed the market in 2022. But he hasn’t done it with a “traditional” method… For a limited time, he’s sharing a free over-the-shoulder “demo” of his strategy in action. It takes less than 10 seconds…
November 1, 2022 | finance.yahoo.com
Myriad Genetics Q3 Earnings Fall Short Of Expectations, Lowers Annual Outlook
November 1, 2022 | finanznachrichten.de
Myriad Genetics, Inc.: Myriad Genetics Reports Third Quarter Financial Results
November 1, 2022 | marketwatch.com
Myriad Genetics Shares Drop 18% on Lower 2022 Guidance
November 1, 2022 | msn.com
Myriad Genetics: Q3 Earnings Insights
November 1, 2022 | finance.yahoo.com
Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member
November 1, 2022 | finance.yahoo.com
Myriad Genetics Reports Third Quarter Financial Results
November 1, 2022 | finance.yahoo.com
Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test
November 1, 2022 | finance.yahoo.com
Myriad Genetics (MYGN) Reports Q3 Loss, Lags Revenue Estimates
October 31, 2022 | msn.com
Earnings Preview: Myriad Genetics
October 26, 2022 | finance.yahoo.com
Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022
September 28, 2022 | finance.yahoo.com
Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds
August 31, 2022 | finance.yahoo.com
New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
August 25, 2022 | finance.yahoo.com
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer
August 22, 2022 | nasdaq.com
Notable Two Hundred Day Moving Average Cross - MYGN
August 21, 2022 | finance.yahoo.com
Is Myriad Genetics, Inc. (NASDAQ:MYGN) Expensive For A Reason? A Look At Its Intrinsic Value
August 19, 2022 | msn.com
This Unpopular Move Could Save Invitae
August 18, 2022 | money.usnews.com
Myriad Genetics, Inc.
August 16, 2022 | finance.yahoo.com
Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

MYGN Company Calendar

Last Earnings
11/01/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
CIK
899923
Web
www.myriad.com
Phone
(801) 584-3600
Fax
801-584-3640
Employees
2,400
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$25.50
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+21.8%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,200,000.00
Net Margins
-11.69%
Pretax Margin
-19.96%
Return on Equity
-4.86%
Return on Assets
-3.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.73
Quick Ratio
2.58

Sales & Book Value

Annual Sales
$690.60 million
Price / Sales
2.46
Cash Flow
$0.47 per share
Price / Cash Flow
44.78
Book Value
$11.31 per share
Price / Book
1.85

Miscellaneous

Outstanding Shares
81,030,000
Free Float
79,575,000
Market Cap
$1.70 billion
Optionable
Optionable
Beta
1.68

Social Links


Key Executives

  • Mr. Paul J. Diaz (Age 60)
    CEO, Pres & Director
    Comp: $2.92M
  • Mr. R. Bryan Riggsbee (Age 51)
    Exec. VP, CFO & Treasurer
    Comp: $934.49k
  • Ms. Nicole LambertMs. Nicole Lambert (Age 48)
    Chief Operating Officer
    Comp: $825.23k
  • Mr. Mark S. Verratti (Age 54)
    Chief Commercial Officer
    Comp: $723.29k
  • Ms. Natalie Munk (Age 41)
    Principal Accounting Officer
  • Dr. Kevin Richard Haas (Age 36)
    Chief Technology Officer
  • Dr. Dale Muzzey Ph.D. (Age 42)
    Chief Scientific Officer
  • Mr. Scott Gleason (Age 43)
    Sr. VP of Investor Relations
  • Dr. Clivetty Martinez
    Chief Compliance Officer
  • Ms. Pamela Wong (Age 54)
    Chief Legal Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MYGN Stock - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings or view top-rated stocks.

What is Myriad Genetics' stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price targets for Myriad Genetics' shares. Their MYGN share price forecasts range from $22.00 to $32.00. On average, they anticipate the company's share price to reach $25.50 in the next year. This suggests a possible upside of 21.8% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2022?

Myriad Genetics' stock was trading at $27.60 at the start of the year. Since then, MYGN shares have decreased by 24.2% and is now trading at $20.93.
View the best growth stocks for 2022 here.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MYGN earnings forecast.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings results on Tuesday, November, 1st. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.12. The firm earned $156.40 million during the quarter, compared to analysts' expectations of $172.12 million. Myriad Genetics had a negative trailing twelve-month return on equity of 4.86% and a negative net margin of 11.69%.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of -$0.35--$0.30 for the period, compared to the consensus estimate of -$0.06. The company issued revenue guidance of $668.00 million-$672.00 million, compared to the consensus revenue estimate of $692.18 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (18.00%), Vanguard Group Inc. (11.26%), State Street Corp (5.75%), Artisan Partners Limited Partnership (3.30%), Dimensional Fund Advisors LP (3.00%) and Disciplined Growth Investors Inc. MN (2.81%). Insiders that own company stock include Alexander Ford, Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Paul Parkinson, Richard Bryan Riggsbee, S Louise Phanstiel and Walter Phd Gilbert.
View institutional ownership trends.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $20.93.

How much money does Myriad Genetics make?

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.70 billion and generates $690.60 million in revenue each year. The company earns $-27,200,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How many employees does Myriad Genetics have?

The company employs 2,400 workers across the globe.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.

This page (NASDAQ:MYGN) was last updated on 12/4/2022 by MarketBeat.com Staff